Kiora Pharmaceuticals, Inc.
KPRX
$3.32
$0.03090.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -33.21% | 21.40% | -34.87% | 240.79% | -397.75% |
| Gross Profit | 33.21% | -21.40% | 36.30% | 3,409.67% | 397.75% |
| SG&A Expenses | 50.68% | -2.46% | 40.16% | 2.12% | -50.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.80% | 7.89% | -1.80% | 63.38% | -23.95% |
| Operating Income | -25.80% | -7.89% | 2.60% | 873.55% | 23.95% |
| Income Before Tax | 0.91% | 40.77% | 15.00% | 820.00% | 16.59% |
| Income Tax Expenses | 2,186.82% | -- | -- | -- | 179.91% |
| Earnings from Continuing Operations | -86.17% | 40.77% | 15.00% | 820.00% | 9.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.17% | 40.77% | 15.00% | 820.00% | 9.20% |
| EBIT | -25.80% | -7.89% | 2.60% | 873.55% | 23.95% |
| EBITDA | -26.00% | -8.30% | 1.97% | 878.39% | 23.95% |
| EPS Basic | 63.10% | 89.84% | 92.55% | 151.73% | 82.84% |
| Normalized Basic EPS | 80.49% | 79.95% | 92.54% | 158.19% | 85.29% |
| EPS Diluted | 63.12% | 89.84% | 92.55% | 137.90% | 82.84% |
| Normalized Diluted EPS | 80.49% | 79.95% | 92.54% | 143.09% | 85.29% |
| Average Basic Shares Outstanding | 404.57% | 433.75% | 1,041.07% | 1,291.50% | 429.11% |
| Average Diluted Shares Outstanding | 404.57% | 433.75% | 1,041.07% | 1,779.14% | 429.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |